Johnson & Johnson is nearing a deal to acquire U.S. cancer drugmaker Pharmacyclics.» Read More
CNBC's Meg Tirrell reports on hottest new technologies from the annual meeting of the American Society of Hematology.
Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.
The American Society of Hematology is holding a massive conference in San Francisco on Saturday. CNBC's Meg Tirrell tells why pharma and biotech investors are paying close attention.
Much of the influenza virus in the U.S. has mutated and this year's vaccine doesn't provide good protection against it, NBC News reports.
Biogen Idec said its experimental medicine for Alzheimer's disease showed promise, prompting it to move "aggressively" into the most advanced stage of studies.
Google-backed genetic testing service 23andMe is launching in the U.K., with the CEO pledging that data would not be shared with Google.
Using flawless English and an insider’s knowledge of Wall Street, the cybercriminals have gained access to the inboxes of top health care executives.
GSK will ax hundreds of U.S. jobs in its biggest market as the drugmaker starts implementing a major cost-saving program.
Pfizer's attempt to take over AstraZeneca through a $110 billion bid would have run aground on changes to U.S. tax laws, even if the companies had reached a deal.
An experimental Ebola vaccine made by GlaxoSmithKline caused no serious side effects, scientists reported on Wednesday.
Strongbody Apparel is selling activewear treated with technology from crab and shrimp shells to prevent odors and wrinkles.
There are few new cancer drugs to treat kids, and not much research is being done.
Look to your left. Look to your right. At least one of you probably drinks too much, according to the Centers for Disease Control and Prevention.
After drug company Sanofi removed CEO Chris Viehbacher, investors question the future of the company's growth and future.
The CDC has taken down a website that offered to help American bosses tally financial losses linked to their overweight employees, NBC News reports.
Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.
The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.
Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.
Actavis is nearing a deal to acquire Allergan in a cash and stock deal worth more than $210 per Allergan share, sources tell CNBC.
NASH, or nonalcoholic steatohepatitis, is a liver disease that may affect as much as 12 percent of the U.S. population, Genfit's Dean Hum said.
Get the best of CNBC in your inbox